COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings

By: Quiver EarningsTracker

Posted: 16 minutes ago / March 26, 2026 11:55 a.m. UTC

COGNITION THERAPEUTICS ($CGTX) posted quarterly earnings results for Q4 2025 on Thursday, March 26th. The company reported earnings of -$0.02 per share, beating estimates of -$0.09 by $0.07. The company also reported revenue of $0, equaling estimates of $0 by $0.

You can see Quiver Quantitative’s $CGTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

COGNITION THERAPEUTICS Hedge Fund Activity

We have seen 34 institutional investors add shares of COGNITION THERAPEUTICS stock to their portfolio, and 29 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 2,042,815 shares (+11695.3%) to their portfolio in Q4 2025, for an estimated $2,757,800
• TANG CAPITAL MANAGEMENT LLC removed 1,200,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,620,000
• ACADIAN ASSET MANAGEMENT LLC removed 701,940 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $947,619
• VANGUARD GROUP INC added 635,912 shares (+23.7%) to their portfolio in Q4 2025, for an estimated $858,481
• MILLENNIUM MANAGEMENT LLC removed 495,896 shares (-88.5%) from their portfolio in Q4 2025, for an estimated $669,459
• DAUNTLESS INVESTMENT GROUP, LLC added 466,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $629,100
• JANE STREET GROUP, LLC removed 311,889 shares (-33.7%) from their portfolio in Q4 2025, for an estimated $421,050

To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard.

COGNITION THERAPEUTICS Analyst Ratings

Wall Street analysts have issued reports on $CGTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• HC Wainwright & Co. issued a “Buy” rating on 12/04/2025
• B. Riley Securities issued a “Buy” rating on 11/21/2025

To track analyst ratings and price targets for COGNITION THERAPEUTICS, check out Quiver Quantitative’s $CGTX forecast page.

COGNITION THERAPEUTICS Price Targets

Multiple analysts have issued price targets for $CGTX recently. We have seen 2 analysts offer price targets for $CGTX in the last 6 months, with a median target of $3.0.

Here are some recent targets:

• Raghuram Selvaraju from HC Wainwright & Co. set a target price of $3.0 on 12/04/2025
• William Woods from B. Riley Securities set a target price of $3.0 on 11/21/2025

This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.